undamentalytics Newsletter
Sign in

Arvinas, Inc. revenue

Arvinas, Inc.'s revenue was $263m in fiscal 2025, down 0.3% on the year before. Since fiscal 2017 ($7.6m) it has grown at a compound 55.8% a year. Over the last twelve months it was $317m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue81443265413179263263317
Growth on the year before—+89.0%+200.2%−39.8%+106.9%+145.1%−40.3%+235.5%−0.3%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Arvinas, Inc. $317m -15.0% 26.1%
Iovance Biotherapeutics, Inc. $325m 34.5% —
Adaptive Biotechnologies Corp $308m 50.1% 17.6%
Vericel Corp $306m 23.0% 19.8%
Vir Biotechnology, Inc. $303m 1495.9% -14.8%
Syndax Pharmaceuticals Inc $290m 159.7% 177.8%

Compare with peers

Head to head: ARVN vs IOVAADPT vs ARVNARVN vs VCELARVN vs VIR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Arvinas, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Arvinas, Inc.